Aetna modified CPB 0963 for luspatercept-aamt (Reblozyl), effective December 6, 2025. Here's what billing teams need to know before submitting claims under J0896.
Aetna, a CVS Health company, updated its luspatercept-aamt (Reblozyl) coverage policy under CPB 0963 Aetna system, affecting claims billed with HCPCS J0896 and administration code CPT 96372. The update clarifies medical necessity criteria across three covered indications—beta thalassemia, myelodysplastic syndrome, and myelofibrosis-associated anemia—and draws hard lines on what Aetna will not cover. If your practice treats hematology or oncology patients on Aetna commercial plans, this change directly affects your prior authorization process and your exposure to claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Luspatercept-aamt (Reblozyl) — CPB 0963 |
| Policy Code | CPB 0963 |
| Change Type | Modified |
| Effective Date | December 6, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Specialists in beta thalassemia treatment |
| Key Action | Update your prior authorization workflow for J0896 and verify all three indication-specific criteria are documented before submitting. |
Aetna Luspatercept-aamt Coverage Criteria and Medical Necessity Requirements 2025
The Aetna luspatercept-aamt coverage policy covers three indications under CPB 0963. Each one has its own distinct set of requirements. Meeting the general diagnosis isn't enough — your documentation has to hit every criterion listed for the specific indication.
Precertification is required for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277 to start the process. Missing this step before administering Reblozyl and billing J0896 guarantees a denial.
Prescriber Qualification Requirement
Aetna requires that a hematologist, oncologist, or beta thalassemia specialist prescribe or consult on the order. A primary care provider writing the script alone won't satisfy this requirement. Document the consulting specialist in the record before submitting for prior authorization.
Indication 1: Anemia with Beta Thalassemia
This indication covers adults 18 and older. All three criteria must be met — not just one or two.
Criterion 1: The member has symptomatic anemia with a pretreatment or pretransfusion hemoglobin (Hgb) of 11 g/dL or less.
Criterion 2: Beta thalassemia (β-thalassemia) or hemoglobin E/β-thalassemia is confirmed by one of the following: hemoglobin electrophoresis or high-performance liquid chromatography (HPLC), or molecular genetic testing. CPT codes 81361, 81362, 81363, and 81364 cover HBB molecular genetic testing and are listed as related codes under this policy. If your lab billed one of those codes to confirm the diagnosis, make sure that result is referenced in your auth request.
Criterion 3: The member received at least six RBC units transfused in the previous 24 weeks.
One practical note on the Hgb threshold: if a transfusion occurred before dosing, Aetna uses the pretransfusion Hgb for dosing purposes. Make sure your documentation captures pre-transfusion labs, not post-transfusion values.
Indication 2: Anemia of Myelodysplastic Syndrome or MDS/MPN
This indication also requires adults 18 and older. Three criteria must all be met.
Criterion 1 (either/or): The member has very low- to intermediate-risk myelodysplastic syndrome, or myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ICD-10 codes D46.0 through D46.Z cover the MDS range. C94.6 captures myelodysplastic disease not elsewhere classified.
Criterion 2: Symptomatic anemia with a pretreatment or pretransfusion Hgb of 11 g/dL or less. Same threshold as beta thalassemia.
Criterion 3: The member receives regular RBC transfusions, defined as two or more units per eight weeks. This is a tighter definition than it sounds. "Regular transfusions" isn't enough — you need the frequency documented against that specific threshold.
Indication 3: Myelofibrosis-Associated Anemia
Aetna covers myelofibrosis-associated anemia as a third indication. The policy lists it but does not provide detailed sub-criteria in the same format as the other two indications. ICD-10 D75.81 (myelofibrosis) is the relevant diagnosis code here.
If you treat myelofibrosis patients and plan to bill J0896 under this indication, talk to your compliance officer before the effective date. The lack of specific sub-criteria in the policy language creates ambiguity about what documentation Aetna expects for prior auth.
Continuation of Therapy
Aetna covers continuation of Reblozyl therapy when two criteria are both met: the member has achieved or maintained a reduction in RBC transfusion burden, and the member has not experienced unacceptable toxicity from Reblozyl. Your continuation auth requests need documented evidence of transfusion burden reduction — not just "patient is tolerating therapy."
Aetna Luspatercept-aamt Exclusions and Non-Covered Indications
Two diagnoses are explicitly excluded from coverage under this policy. There are no exceptions listed in this policy for either excluded diagnosis.
Alpha-thalassemia (ICD-10 D56.0) is not covered. Aetna lists it in the exclusions section, not just as an uncovered indication. If a member has alpha-thalassemia and you bill J0896, expect a denial.
Hemoglobin S/β-thalassemia is also excluded. This is distinct from hemoglobin E/β-thalassemia, which is covered under the beta thalassemia indication. The distinction matters — confirm the exact diagnosis type from the lab report before billing.
All other indications not listed in Section II of CPB 0963 are classified as experimental, investigational, or unproven. Aetna makes no exceptions for off-label use in the policy text.
Coverage Indications at a Glance
| Indication | Status | Key Codes | Notes |
|---|---|---|---|
| Anemia with beta thalassemia (age ≥18) | Covered | J0896, D56.1, D56.5, 81361–81364 | Hgb ≤11 g/dL + confirmed diagnosis + ≥6 RBC units/24 weeks; prior auth required |
| Anemia of MDS (very low- to intermediate-risk) | Covered | J0896, D46.0–D46.Z | Hgb ≤11 g/dL + ≥2 RBC units/8 weeks; prior auth required |
| MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) | Covered | J0896, D46.Z, C94.6 | Same anemia and transfusion criteria as MDS; prior auth required |
| Myelofibrosis-associated anemia | Covered | J0896, D75.81 | Sub-criteria not detailed in policy; confirm documentation requirements with compliance |
| Alpha-thalassemia | Not Covered | D56.0 | Explicitly excluded |
| Hemoglobin S/β-thalassemia | Excluded indication — verify before billing | D57 series (codes appear in policy code table without coverage group assignment) | Policy text excludes hemoglobin S/β-thalassemia as an indication; D57 codes listed in source without covered/not-covered label — confirm exact diagnosis subtype with treating physician and compliance officer before submitting |
| All other indications | Experimental / Not Covered | — | Aetna considers unproven; no exceptions listed |
Aetna Luspatercept-aamt Billing Guidelines and Action Items 2025
These are the steps your billing team needs to take before December 6, 2025.
| # | Action Item |
|---|---|
| 1 | Audit all active Reblozyl prior authorizations on Aetna commercial plans. Confirm each auth was issued under one of the three covered indications. If any auth doesn't map cleanly to beta thalassemia, MDS/MPN, or myelofibrosis, flag it for review before the next administration date. |
| 2 | Update your prior authorization checklist for J0896. Your checklist needs separate sections for each indication. Beta thalassemia requires six RBC units in 24 weeks. MDS/MPN requires two units per eight weeks. These thresholds are different — using the wrong one on an auth request is a fast path to denial. |
| 3 | Confirm lab documentation for beta thalassemia diagnosis. Aetna requires confirmation by hemoglobin electrophoresis or HPLC, or by molecular genetic testing (CPT 81361–81364). These are two distinct acceptable pathways — either one satisfies the requirement. If your records only show a clinical diagnosis without lab confirmation, get the appropriate testing ordered and documented before submitting the auth. |
| 4 | Verify prescriber credentials before submitting any new auth. The ordering provider must be a hematologist, oncologist, or beta thalassemia specialist, or a consulting specialist must be documented. Audit your existing orders and flag any that came from a primary care provider without a specialist consult on record. |
| 5 | Check diagnosis codes on all Aetna claims billed with J0896. Alpha-thalassemia (D56.0) triggers automatic exclusion. If any of your billed claims carried this code, pull them now. A submitted claim with an excluded diagnosis code will deny — and a paid claim that gets retroactively audited creates a reimbursement recovery risk. |
| 6 | Build a continuation auth template that documents transfusion burden reduction. Don't wait until the renewal request is due. Set up your clinical documentation workflow now so providers are capturing transfusion frequency data at each visit. Aetna's continuation criteria hinge on documented reduction — not just absence of adverse events. |
| 7 | If you treat myelofibrosis patients under this indication, loop in your compliance officer. The policy covers myelofibrosis-associated anemia but doesn't specify sub-criteria. That ambiguity in Aetna's luspatercept billing guidelines increases your denial risk. Get clarity on what documentation Aetna's reviewers expect before you submit. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Luspatercept-aamt Under CPB 0963
HCPCS Codes Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J0896 | HCPCS | Injection, luspatercept-aamt, 0.25 mg |
CPT Codes Related to CPB 0963
| Code | Type | Description |
|---|---|---|
| 81361 | CPT | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy) |
| 81362 | CPT | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy) |
| 81363 | CPT | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy) |
| 81364 | CPT | HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy) |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C94.6 | Myelodysplastic disease, not elsewhere classified |
| D46.0–D46.Z | Myelodysplastic syndromes |
| D56.0 | Alpha thalassemia (excluded — not covered) |
| D56.1 | Beta thalassemia |
| D56.3 | Thalassemia minor |
| D56.5 | Hemoglobin E-beta thalassemia |
| D56.8 | Other thalassemias |
| D57.42 | Sickle-cell thalassemia beta zero without crisis |
| D57.431–D57.439 | Sickle-cell thalassemia beta zero with crisis (multiple specificity codes) |
| D57.44 | Sickle-cell thalassemia beta plus without crisis |
| D57.451–D57.459 | Sickle-cell thalassemia beta plus with crisis (multiple specificity codes) |
| D75.81 | Myelofibrosis |
One important flag on the D57 codes: the policy text excludes hemoglobin S/β-thalassemia as an indication, but D57 codes appear in the policy code table without a covered or not-covered group label. If you're billing Reblozyl for a patient with a D57-series code, confirm the exact diagnosis subtype with the treating physician and your compliance officer before submitting. Don't assume coverage or exclusion based on the code alone.
Get the Full Picture for CPT 96372
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.